Therefore we speculated that miR-185 could down-regulate anti-β1-AR antibody production by inhibiting CD4 T cell development, which influenced MHC class II antigen presentation pathway in DCM patients. The gene discussed is ADRB1; the disease is familial dilated cardiomyopathy.